Overview of our international portfolio

Magnetic resonance imaging (MRI) uses spatially varying magnetic fields and radio waves to produce cross-sectional, two and three-dimensional images of organs and internal body structures. An MRI does not use ionising radiation, making it the preferred technique for children and patients who require multiple imaging examinations. An MRI is also appropriate for investigating soft tissue, such as ligament and tendon injuries, brain tumours and spinal cord injuries.

Molecular imaging via positron emission tomography-computerised tomography (PET-CT) injects a radiopharmaceutical into a patient which localises in a specific organ or system within the body. Radiopharmaceuticals emit minuscule amounts of measurable positron radiation that are captured by a PET camera which, in turn, generates an image of the specific organ or system for the clinician to assess. Doctors use these images to identify small changes in body tissues at a cellular level by highlighting physiological processes rather than anatomical structures. PET‑CT combines the high-quality resolution of the patient’s anatomy using CT with the ability to measure the metabolic activity of cells. The metabolic activity helps clinicians better understand changes at the cellular level, which could be early indications of cancer. This has proven invaluable in helping oncologists make more accurate diagnosis and staging assessments, choosing the most appropriate therapies and determining which therapy is an effective treatment for cancer. PET-CT is also used to identify other degenerative conditions, such as cardiac and neurological diseases.

We manufacture the radiopharmaceuticals used in molecular imaging procedures in radiopharmacy. Radiopharmaceuticals are usually manufactured in a cyclotron, a type of particle accelerator.